China Updates “Blacklist” System To Crack Down On Commercial Bribery In Drug And Device Industries
This article was originally published in The Pink Sheet Daily
Executive Summary
China’s NHFPC will update its blacklist system to regulate pharma and device companies’ commercial operations in the country. The updated system will transform China’s provincial blacklist system to a nationwide network.